Back to Browse Journals » Core Evidence » Volume 5

Panitumumab: the evidence for its use in the treatment of metastatic colorectal cancer

Authors Rossana Berardi, Azzurra Onofri, Mirco Pistelli, et al

Published Date September 2010 Volume 2010:5 Pages 61—76

DOI http://dx.doi.org/10.2147/CE.S7035

Published 24 September 2010

Rossana Berardi1, Azzurra Onofri2, Mirco Pistelli2, Elena Maccaroni2, Mario Scartozzi1, Chiara Pierantoni1, Stefano Cascinu1
1Clinica di Oncologia Medica, Università Politecnica delle Marche, Ospedali Riuniti Umberto I-GM Lancisi-G Salesi di Ancona, Italy; 2Scuola di Specializzazione in Oncologia Medica, Università Politecnica delle Marche, Ancona, Italy

Abstract: Panitumumab is the first fully human monoclonal antibody to Epidermal Growth Factor Receptor (EGFR) to enter clinical trials for the treatment of solid tumors. The anti-tumor activity of panitumumab has been tested in vitro and in vivo, and inhibition of tumor growth has been observed in numerous cancer models, particularly lung, kidney and colorectal (CRC). Preclinical and clinical studies have established a role for panitumumab in metastatic colorectal cancer (mCRC) refractory to multiple chemotherapeutic regimens. Based on these encouraging findings, panitumumab was approved by the US Food and Drug Administration for the treatment of patients with epidermal growth factor receptor-expressing mCRC refractory to fluoropyrimidine-, oxaliplatin-, and/or irinotecan-containing chemotherapeutic regimens. The improvement in progression free survival (PFS) and response rate (RR) produced by panitumumab monotherapy was significantly greater in patients with non mutated (wild-type) K-RAS than in those with mutant K-RAS. Therefore implementing routine K-RAS screening and limiting the use of EGFR inhibitors to patients with wild-type K-RAS appears the better strategy for select only the patients who could benefit from the therapy with panitumumab and also may have the potential for cost savings. The purpose of this review was to evaluate the patient-related, disease-related and economic-related evidence for the use of panitumumab in the treatment of metastatic colorectal cancer in clinical practice.

Keywords: colorectal cancer, EGFR; K-RAS, panitumumab
 

Download Article [PDF] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php

Other article by this author:

Novel small molecule EGFR inhibitors as candidate drugs in non-small cell lung cancer

Berardi R, Santoni M, Morgese F, Ballatore Z, Savini A, Onofri A, Mazzanti P, Pistelli M, Pierantoni C, De Lisa M, Caramanti M, Pagliaretta S, Pellei C, Cascinu S

OncoTargets and Therapy 2013, 6:563-576

Published Date: 21 May 2013

Readers of this article also read:

Lower irritation microemulsion-based rotigotine gel: formulation optimization and in vitro and in vivo studies

Wang Z, Mu HJ, Zhang XM, Ma PK, Lian SN, Zhang FP, Chu SY, Zhang WW, Wang AP, Wang WY, Sun KX

International Journal of Nanomedicine 2015, 10:633-644

Published Date: 14 January 2015

Prostaglandin-associated periorbitopathy in latanoprost users

Nakakura S, Yamamoto M, Terao E, Nagatomi N, Matsuo N, Fujisawa Y, Fujio Y, Tabuchi H, Kiuchi Y

Clinical Ophthalmology 2015, 9:51-56

Published Date: 30 December 2014

Using poly(lactic-co-glycolic acid) microspheres to encapsulate plasmid of bone morphogenetic protein 2/polyethylenimine nanoparticles to promote bone formation in vitro and in vivo

Qiao C, Zhang K, Jin H, Miao L, Shi C, Liu X, Yuan A, Liu J, Li D, Zheng C, Zhang G, Li X, Yang B, Sun H

International Journal of Nanomedicine 2013, 8:2985-2995

Published Date: 13 August 2013

Peptide ligand and PEG-mediated long-circulating liposome targeted to FGFR overexpressing tumor in vivo

Cai L, Wang X, Wang W, Qiu N, Wen J, Duan X, Li X, Chen X, Yang L, Qian Z, Wei Y, Chen L

International Journal of Nanomedicine 2012, 7:4499-4510

Published Date: 14 August 2012

Corrigendum

De Caterina AR, Harper AR, Cuculi F

Vascular Health and Risk Management 2012, 8:443-445

Published Date: 19 July 2012

Retraction

Singhai R

Breast Cancer: Targets and Therapy 2012, 4:33-34

Published Date: 8 March 2012

Stiffness of the large arteries in individuals with and without Down syndrome

Rodrigues AN, Coelho LC, Goncalves WLS, Gouvea SA, Vasconcellos MJR, Cunha RS, Abreu GR

Vascular Health and Risk Management 2011, 7:375-381

Published Date: 9 June 2011

Food nanotechnology – an overview

Bhupinder S Sekhon

Nanotechnology, Science and Applications 2010, 3:1-15

Published Date: 4 May 2010